Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec;593(24):3449-3460.
doi: 10.1002/1873-3468.13649. Epub 2019 Nov 15.

Interaction of adenovirus with antibodies, complement, and coagulation factors

Rondine J Allen  1 , Andrew P Byrnes  1
Affiliations
Free article
Review

Interaction of adenovirus with antibodies, complement, and coagulation factors

Rondine J Allen et al. FEBS Lett. 2019 Dec.
Free article

Abstract

Adenovirus (AdV) is one of the most widely used vectors for gene therapy and vaccine studies due to its excellent transduction efficiency, capacity for large transgenes, and high levels of gene expression. When administered intravascularly, the fate of AdV vectors is heavily influenced by interactions with host plasma proteins. Some plasma proteins can neutralize AdV, but AdV can also specifically bind plasma proteins that protect against neutralization and preserve activity. This review summarizes the plasma proteins that interact with AdV, including antibodies, complement, and vitamin K-dependent coagulation factors. We will also review the complex interactions of these plasma proteins with each other and with cellular proteins, as well as strategies for developing better AdV vectors that evade or manipulate plasma proteins.

Keywords: adenovirus; complement; gene therapy; immunoglobulin G; immunoglobulin M; natural antibody; tripartite motif-containing protein 21; vitamin K-dependent coagulation factors.

PubMed Disclaimer

References

    1. Byrnes AP (2016) Antibodies against adenoviruses. In Adenovirus Vectors for Gene Therapy, 2nd edn (Curiel D, ed), pp. 367-390. Elsevier, London, UK.
    1. Lopez-Gordo E, Podgorski II, Downes N and Alemany R (2014) Circumventing antivector immunity: potential use of nonhuman adenoviral vectors. Hum Gene Ther 25, 285-300.
    1. Atasheva S and Shayakhmetov DM (2016) Adenovirus sensing by the immune system. Curr Opin Virol 21, 109-113.
    1. Ma J, Duffy MR, Deng L, Dakin RS, Uil T, Custers J, Kelly SM, McVey JH, Nicklin SA and Baker AH (2015) Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo. PLoS Pathog 11, e1004673.
    1. Xu Z, Qiu Q, Tian J, Smith JS, Conenello GM, Morita T and Byrnes AP (2013) Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat Med 19, 452-457.

Publication types

MeSH terms

LinkOut - more resources